Long-term clarithromycin in cystic fibrosis: Effects on inflammatory markers in BAL and clinical status

Turkish Journal of Pediatrics

Volumn 51, Issue 5, 2009, Pages 416-423

  Doǧru, Deniz ^a   Dalgiç, Fuheda ^a   Kiper, Nural ^a   Özçelik, Uǧur ^a   Yalçin, Ebru ^a   Aslan, Ayşe Tana ^a   Gürcan, Nermin ^a   Saricaoǧlu, Fatma ^a   Gür, Deniz ^a   Karayazgan, Yasemin ^a   Firat, Pinar ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Clarithromycin; Clinical status; Cystic fibrosis; Inflammation

Indexed keywords

CHLORIDE; CLARITHROMYCIN; INTERLEUKIN 8; LEUKOCYTE ELASTASE; NORADRENALIN; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ARTICLE; BODY WEIGHT; CELL COUNT; CHILD; CHRONIC DRUG ADMINISTRATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYSTIC FIBROSIS; CYTOKINE RELEASE; DISEASE EXACERBATION; DISEASE MARKER; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENZYME BLOOD LEVEL; EOSINOPHIL COUNT; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HUMAN; LONG TERM CARE; LUNG FUNCTION TEST; LUNG LAVAGE; LYMPHOCYTE COUNT; MACROPHAGE; MALE; NEUTROPHIL COUNT; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; RASH; TREATMENT DURATION;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL MARKERS; BRONCHOALVEOLAR LAVAGE; BRONCHOALVEOLAR LAVAGE FLUID; CHILD; CHILD, PRESCHOOL; CLARITHROMYCIN; CROSS-OVER STUDIES; CYSTIC FIBROSIS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HEALTH STATUS; HUMANS; INTERLEUKIN-8; LEUKOCYTE ELASTASE; MALE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 76149122129     PISSN: 00414301     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Schoni MH. Macrolide antibiotic therapy in patients with cystic fibrosis. Swiss Med Wkly 2003; 133: 297-301.
2. Schultz MJ. Macrolide activities beyond their antimicrobial effects: macrolides in diffuse panbronchiolitis and cystic fibrosis. J Antimicrob Chemother 2004; 54: 21-28.
3. Sockrider M, Swank PR, Seilheimer DK, Schidlow DW. Measuring clinical status in cystic fibrosis: internal validity and reliability of a modified NIH score. Pediatr Pulmonol 1994; 17: 86-96.
4. De Blic J, Midulla F, Barbato A, et al. Bronchoalveolar lavage in children. ERS Task Force on bronchoalveolar lavage in children. ERJ 2000; 15: 217-231.
5. Jaffe A, Francis J, Rosenthal M, Bush A. Long-term azithromycin may improve lung function in children with cystic fibrosis. Lancet 1998; 351: 420.
6. Ordonez C, Stulbarg M, Grundland H, Liu J, Boushey H. Effect of clarithromycin on airway obstruction and inflammatory markers in induced sputum in cystic fibrosis: a pilot study. Pediatr Pulmonol 2001; 32: 29-37.
7. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 2002; 360: 978-984.
8. Wolter J, Seeney S, Bell S, et al. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002; 57: 212-216.
9. Saiman L, Marshall BC, Mayer-Hamblett N, et al. Macrolide Study Group. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003; 290: 1749-1756.
10. Wolter JM, Seeny SL, McCormack JG. Macrolides in cystic fibrosis. Is there a role? Am J Respir Med 2002; 1: 235-241.
11. Bonfield TL, Panuska JR, Konstan MW, et al. Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Med 1995; 152: 2111-2118.
12. Noah TL, Black HR, Cheng PW, Wood RE, Leigh MW. Nasal and bronchoalveolar lavage fluid cytokines in early cystic fibrosis. J Infect Dis 1997; 175: 638-647.
13. Salva PS, Doyle NA, Graham L, Eigen H, Doerschuk CM. TNF-alpha, IL-8, soluble ICAM-1, and neutrophils in sputum of cystic fibrosis patients. Pediatr Pulmonol 1996; 21: 9-11.
14. Dean TP, Dai Y, Shute JK, Church MK, Warner JO. Interleukin-8 concentrations are elevated in bronchoalveolar lavage, sputum, and sera of children with cystic fibrosis. Pediatr Res 1993; 34: 159-161.
15. Bell SC, McCormack JG, Yang IA, et al. Azithromycin (AZM) reduces TNF-α release from lipopolysaccharide (LPS)-stimulated mononuclear cells (PBMC) in cystic fibrosis (CF). Pediatr Pulmonol 2000; 20: S 261.
16. Everard ML, Sly P, Brenan S, Ryan G. Macrolide antibiotics in diffuse panbronchiolitis and in cystic fibrosis. ERJ 1997; 10: 2926.
17. Muhlebach MS, Stewart PW, Leigh MW, Noah TL. Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients. Am J Respir Med 1999; 160: 186-191.
18. Pirzada OM, Taylor CJ. Long term macrolide antibiotics improve pulmonary function in cystic fibrosis. Pediatr Pulmonol 1999; 29: S263.
19. Pirzada OM, McGaw J, Taylor CJ. Improved lung function and body mass index associated with long-term use of macrolide antibiotics. J Cyst Fibros 2003; 2: 69-71.
20. Zhanel G, Dueck M, Hoban D, et al. Review of macrolides and ketolides. Drugs 2001; 61: 443-498.